CLINICAL TRIALS PROFILE FOR ARGATROBAN IN SODIUM CHLORIDE

All Clinical Trials for ARGATROBAN IN SODIUM CHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00035178 ↗	Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis	Completed	Texas Biotechnology Corporation	Phase 4	2002-05-01	The primary goals of this investigation are to provide guidance on how to dose Argatroban in patients undergoing hemodialysis and to assess the safety and tolerability of Argatroban in hemodialysis patients. The secondary goal of the study will be to assess the adequacy of anticoagulation during hemodialysis.
NCT00039858 ↗	Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin	Completed	GlaxoSmithKline	Phase 4	2003-09-01	The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who in the opinion of the investigator require alternative anticoagulation due to an underlying condition.
NCT00039858 ↗	Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin	Completed	Encysive Pharmaceuticals	Phase 4	2003-09-01	The purpose of this study is to evaluate the safe and effective dose of Argatroban for prophylaxis and/or treatment of thrombosis in pediatric patients with current or previous diagnosis of heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS), or who in the opinion of the investigator require alternative anticoagulation due to an underlying condition.
NCT00113997 ↗	Safety and Dosing Evaluation of REG1 Anticoagulation System	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 1	2005-06-01	This 1-week study will test the safety and dosing of an anticoagulation system called REG1 that is designed to improve control of "blood thinning." Patients with heart attack and other conditions require treatment with an anticoagulant (blood thinner) to prevent the formation of blood clots. However, anticoagulation therapy can increase the risk of bleeding. The REG1 system is designed to minimize this risk. One part of the system stops the activity of factor IX (a protein that helps blood clot) while the other part of the system (the antidote) inactivates the drug and stops the thinning process. This study will examine in normal healthy subjects how the REG1 system works in the body and how it leaves the body. Healthy normal volunteers between 12 and 65 years of age who weigh 50-120 kilograms (110-264 pounds) and have no history of bleeding problems or significant bleeding may be eligible for this study. Candidates are screened with a medical history, physical examination, and blood tests. Participants must avoid foods that may alter the blood's clotting ability and must not take any medications the week of the study. They undergo the following tests and procedures: Day 1 Subjects are admitted to the NIH Clinical Center for an overnight stay. Two catheters (plastic tubes) are placed in the subject's arm veins, one for drawing blood samples and the other for injecting one of the following: REG1 drug, REG1 antidote, REG1 drug and antidote, or placebo. Two injections of study medication are given, spaced 3 hours apart, each over a 1-minute period. After each injection, blood is collected at specific times to measure levels of the drug or antidote in the body and the blood's ability to clot. Subjects also provide a 24-hour urine collection and stool sample. Day 2 A blood sample is drawn 24 hours after the drug or antidote injection from the previous day. If the blood test result is normal, subjects are discharged home with instructions to follow. They return to the Clinical Center at 36 hours and 48 hours for additional blood samples. Days 3 and 7 A blood sample is collected at the end of day 3 and day 7. Urine and stool samples are also collected.

Clinical Trial Conditions for ARGATROBAN IN SODIUM CHLORIDE

Condition Name

Condition Name for ARGATROBAN IN SODIUM CHLORIDE
Intervention	Trials
Heparin-induced Thrombocytopenia	4
Stroke	3
Ischemic Stroke	3
CVD	2

Condition MeSH

Condition MeSH for ARGATROBAN IN SODIUM CHLORIDE
Intervention	Trials
Thrombocytopenia	10
Stroke	9
Ischemic Stroke	7
Ischemia	6

Clinical Trial Locations for ARGATROBAN IN SODIUM CHLORIDE

Trials by Country

Trials by Country for ARGATROBAN IN SODIUM CHLORIDE
Location	Trials
United States	75
Japan	12
China	10
Germany	9
France	4

Trials by US State

Trials by US State for ARGATROBAN IN SODIUM CHLORIDE
Location	Trials
Texas	6
Ohio	4
Massachusetts	4
Minnesota	4
Illinois	4

Clinical Trial Progress for ARGATROBAN IN SODIUM CHLORIDE

Clinical Trial Phase

Clinical Trial Phase for ARGATROBAN IN SODIUM CHLORIDE
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	15
Phase 3	4

Clinical Trial Status

Clinical Trial Status for ARGATROBAN IN SODIUM CHLORIDE
Clinical Trial Phase	Trials
Completed	18
Recruiting	9
Terminated	6

Clinical Trial Sponsors for ARGATROBAN IN SODIUM CHLORIDE

Sponsor Name

Sponsor Name for ARGATROBAN IN SODIUM CHLORIDE
Sponsor	Trials
Mitsubishi Tanabe Pharma Corporation	3
The University of Texas Health Science Center, Houston	3
GlaxoSmithKline	3

Sponsor Type

Sponsor Type for ARGATROBAN IN SODIUM CHLORIDE
Sponsor	Trials
Other	28
Industry	15
NIH	2

Argatroban in Sodium Chloride: Clinical Trial Update, Market Analysis, and Projections

Last updated: April 28, 2026

What is the product and how is it positioned clinically?

Argatroban in sodium chloride is an intravenous formulation of argatroban, a direct thrombin inhibitor. Clinically, argatroban is used for patients who have or are suspected to have heparin-induced thrombocytopenia (HIT) and require systemic anticoagulation, including settings where transition or continuation of anticoagulation is required.

Formulation context

• Drug substance: Argatroban (direct thrombin inhibitor)
• Dosage form: Intravenous
• Excipients: Delivered in sodium chloride (infusion-compatible solution)

Regulatory positioning

• Argatroban is an established therapy for HIT in major markets; the sodium chloride formulation supports IV administration and is integrated into routine hospital workflows for acute anticoagulation.

---

What does the current clinical trial landscape indicate for argatroban?

Are there ongoing pivotal or late-stage trials specifically for “argatroban in sodium chloride”?

No complete, source-verifiable, public trial set is available here to produce a complete, accurate “current update” for the exact product form (argatroban in sodium chloride) across major registries (e.g., ClinicalTrials.gov, EU CTR) with trial-level timelines, enrollment, endpoints, and status.

How to interpret the absence of form-specific trial signals

Argatroban is a mature, off-patent class product in many jurisdictions. In mature molecules, new trials more often target:

• New indications (rare disease expansions)
• New dosing strategies
• Comparative real-world effectiveness cohorts
• Formulation or supply-chain stability, where the active drug drives approvals and the formulation is secondary

That pattern means that form-specific “late-stage” readouts are uncommon unless a regulator or sponsor changes the delivery system or seeks label expansion.

---

What is the market size and where does demand come from?

Primary demand drivers

1. HIT incidence and acute-care prescribing
   • HIT is uncommon but clinically urgent. Demand concentrates in hospitals with hematology, ICU, and thrombosis services.
2. Direct thrombin inhibitor selection during heparin avoidance
   • When heparin is contraindicated or HIT is suspected, clinicians select anticoagulation alternatives where argatroban has guideline and historical adoption.
3. Healthcare system throughput
   • Argatroban demand tracks hospital case throughput in acute care and the penetration of HIT testing and management pathways.

Pricing and procurement reality (practical market structure)

• Hospital procurement favors consistent IV supply, predictable handling, and pharmacy workflow compatibility.
• Direct procurement typically occurs via national or regional tenders, with substitution dependent on availability, formulary status, and pharmacovigilance preferences.

---

How does competition shape argatroban’s economics?

Direct competitive set

Argatroban competes in the HIT anticoagulation space primarily with other direct thrombin inhibitors and, in practice, with other non-heparin anticoagulants depending on label scope and institution preferences.

Competitive levers that affect market share

• Formulary access (hospital-level)
• Stock reliability and lead times
• Clinical comfort and guideline familiarity
• Pharmacovigilance record and dosing ease

Because argatroban is already embedded in HIT management protocols, competition generally shifts utilization at the margins (hospital-level switching) rather than displacing entirely.

---

What is the IP and lifecycle risk profile?

Lifecycle

• Argatroban as a molecule has a long market presence, which typically implies the original composition and basic manufacturing IP has expired in most major jurisdictions.
• Formulation IP may exist for specific delivery systems, packaging, or manufacturing process improvements, but these rarely prevent generic entry where the active ingredient is mature.

Practical impact

• Investors and buyers should model argatroban demand as a managed, price-pressured, hospital-procured product rather than a high-growth pipeline asset.

---

Market projection: what should be expected over the next 5 years?

Projection framework

Given limited form-specific clinical trial readouts and the mature nature of argatroban:

• Base case assumes stable-to-moderate demand, driven by HIT case management volume and hospital adoption stability.
• Price case assumes compression from substitution and tender-driven procurement.
• Volume case assumes modest growth from increased HIT recognition and testing, offset by outpatient/alternative pathway changes.

5-year market outlook (directional projection)

Use the following directional bands for planning (not point estimates):

Year horizon	Volume trend	Price trend	Net revenue trend
Next 12 months	Stable	Down modestly	Flat to down
2 to 3 years	Low growth	Down	Flat to modest decline
4 to 5 years	Low growth to stable	Down or stable	Low growth or flat

What would change the forecast

• Regulatory label expansion (new HIT subsets or expanded thrombosis contexts)
• Demonstrated superiority via trials or strong comparative real-world evidence that changes guideline positioning
• Supply disruption affecting competitors first, temporarily lifting share

---

Business implications for R&D and investment

1) Clinical development strategy

For a mature active ingredient, the highest-probability “value” is not a brand-new pivotal trial for the molecule, but:

• Comparative outcomes in real-world practice (HIT pathway optimization)
• Safety signal refinement (bleeding and thrombosis endpoints in subpopulations)
• Operational enhancements (stability, packaging, pharmacy usability), if tied to regulatory action

2) Commercial strategy

• Maintain formulary coverage through tender readiness and supply assurance.
• Support protocol adoption: dosing workflows, monitoring templates, and HIT pathway integration.

3) IP strategy

• Focus on defensible manufacturing/process improvements or packaging-specific IP only if they materially affect stability, shelf life, or usability, enabling regulatory leverage and procurement stickiness.

---

Key Takeaways

• Argatroban in sodium chloride is an established IV direct thrombin inhibitor product used for HIT anticoagulation in acute hospital settings.
• Public, form-specific “current trial updates” cannot be produced here without a verifiable dataset; mature products typically show limited late-stage form-specific activity unless labels expand.
• Demand is concentrated in hospital acute-care services and is driven by HIT recognition and anticoagulation pathway adherence.
• Market outlook over the next 5 years should be modeled as stable-to-low growth volume with ongoing price pressure, yielding flat to modest decline net revenue in many scenarios.
• Competitive dynamics center on formulary access, supply reliability, and guideline comfort rather than large-scale differentiation.

---

FAQs

1) Is argatroban in sodium chloride used only for HIT?

Its clinical use centers on HIT anticoagulation; other off-label contexts depend on local practice and label scope.

2) Why is the “sodium chloride” formulation commercially relevant?

Because it supports IV delivery and pharmacy handling within standard hospital infusion workflows, affecting substitution and procurement preferences.

3) What drives market demand most for argatroban?

Hospital acute-care anticoagulation decisions during suspected or confirmed HIT and adherence to HIT management pathways.

4) How does competition affect pricing?

Tender-driven procurement and substitution among anticoagulant alternatives typically compress prices over time, even when clinical demand remains stable.

5) What would most improve revenue growth prospects?

Regulatory label expansion and evidence that changes guideline positioning or switches institutional protocols toward higher utilization.

---

References

[1] Not provided (no verifiable source set was included in the input to support specific trial or market figures).